Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Phillip J MeaseTaylor BlachleyBlessing DubeRobert R McLeanNina KimPeter HurPhilip S HelliwellPublished in: The Journal of rheumatology (2022)
In this real-world population, patients with PsA who received and maintained secukinumab for 6 months achieved MDA in proportions consistent with clinical trials and demonstrated improvements in clinical manifestations and PROs.